BioSpace News Archive

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of June 2020, which is payable on July 15, 2020 to shareholders of record at the close of business on June 30, 2020.

Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED,.

AVITA Medical Limited ACN 058 466 523 is pleased to announce that shareholders voted in favour of the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America, under which AVITA Therapeutics, Inc., a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.

Nanoform Finland Plc announced the appointment of Peter Hänninen as General Counsel, effective as of September 1, 2020.

AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®

Partnership aims to deliver the most comprehensive, cost effective and high throughput cancer sequencing and interpretation service in Europe, to enable improved cancer patient management, treatment, and monitoring

The FUSE Study is designed to demonstrate the superiority of Circumferential Cervical Fusion over traditional ACDF in patients at high risk for nonunion or revisions.

Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will host a virtual Investor R&D Showcase on Tuesday, June 23, 2020 at 3:30 p.m. Pacific Time / 6:30 p.m. Eastern Time. The event will feature an overview of presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II as w

Janpix Inc., a biotechnology company developing monovalent small molecule protein degraders as novel therapeutics, announced the company will present preclinical data showing the characterization of novel, highly selective and potent monovalent degraders of STAT3 & STAT5 proteins.